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ABSTRACT 
Androgen receptor (AR) signaling plays an 
important role in the development and pro-
gression of prostate cancer (PCa).  Importantly, 
AR continues to be expressed in advanced 
castrate-resistant PCa (CRPC), where the AR can 
have ligand-independent activity.  Identification of 
naturally occurring substances that can inhibit 
AR expression holds promise for PCa chemo-
prevention and therapy.  Earlier research demon-
strated that resveratrol (Res) inhibited androgen-
promoted growth, AR expression, and trans-
activation in androgen-responsive non-metastatic 
LNCaP PCa cells.  In the current study, the effects 
of Res and three natural analogs  [trimethoxy-
resveratrol (3M-Res), pterostilbene (Pter), and 
piceatannol (Pic)] were investigated for effects on 
the growth of 22Rv1 castrate-resistant cells that 
express full-length (AR114/110) and truncated 
form (AR80) of AR.  Although all the stilbenes 
tested inhibited the proliferation of 22Rv1 cells in 
a dose-dependent manner, 3M-Res was the most 
potent inhibitor.  While AR114/110 responded to 
the syn-thetic androgen agonist methyltrienolone 
(R1881) as well as to antiandrogen flutamide, 
AR80, which lacks a ligand-binding domain, did not  
 
 
 
respond to R1881, but was inhibited by 
flutamide. Interestingly, Res, Pter, and Pic, but 
not 3M-Res, similar to flutamide, inhibited both 
AR114/110 and AR80 with the effect on AR80 
being more prominent with the use of high 
concentrations of stilbenes.  Collectively, the data 
indicate that both AR-independent (3M-Res) and 
possibly AR-dependent (Res, Pter, and Pic) 
mechanisms of cell growth inhibition occurs via 
these stilbenes.  These findings provide evidence 
for plant-derived stilbenes as attractive and 
promising pharmacologically safe compounds to 
be used for diminishing progression and curb 
worsening of CRPC. 
 
INTRODUCTION 
 Plant-derived polyphenols are attractive clinical 
candidates for cancer prevention and treatment.  
Resveratrol (Res) (trans-3,5,4'-trihydroxystilbene) is 
a polyphenol, a stilbene phytoalexin that is syn-
thesized by a wide variety of plants in response to 
environmental stress and other stressors (Bhat and 
Pezzuto, 2002).  Polygonum cuspidatum (common 
name Kojokon) is one such plant that produces Res  
(Burns et al., 2002).  Res is also produced by grape 
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vines (Vitis vinifera), primarily in the grape berry 
skin (Fremont, 2000).  
 Pterostilbene (Pter) (trans-3,5-dimethoxy-4’-
hydroxystilbene), a natural analog of Res, is a 
constituent in blueberries and grapes (Rimando et al., 
2004), and trimethoxy-resveratrol (3M-Res) (trans-
3,5,4’-trimethoxystilbene) is a constituent in 
Pterobolium hexapatallum (common name Indian 
Redwing) (Wang et al., 2010).  Another naturally 
occurring analog, piceatannol (Pic) (trans-3,4,3’,5’-
tetrahydroxystilbene), which is a constituent in grapes 
and red wine, contains one extra hydroxy group 
(Kang et al., 2011).  Resveratrol has been widely 
studied because of various health benefits associated 
with the compound, such as cardiovascular, 
neuroprotective, anti-inflammatory, antioxidant, and 
anticancer effects (Athar et al., 2007; Harikumar and 
Aggarwal, 2008; Markus and Morris, 2008; Pirola 
and Frojdo, 2008).  In recent years  natural analogs of 
Res have attracted increasing attention as a number of 
studies have suggested that modifications to the 
chemical structure, such as methoxylation-
hydroxylation (Fig. 1) could enhance bioactivity 
(Huang et al., 2007; Kondratyuk et al., 2011; Wilson 
et al., 2008; Gosslau et al., 2008). 
 
Figure 1. Chemical structures of natural stilbenes used in this      
      study. 
Resveratrol (Res), trans-3,4,5’-trihydroxystilbene; Pterostilbene 
(Pter), trans-3,5-dimethoxystilbene; Trimethoxy-Resveratrol 
(3M-Res), trans—3,5,4”-trimethoxystilbene; Piceatannol (Pic), 
trans-3,5,3’4’-tetrahydroxystilbene. 
 Prostate carcinoma, the most commonly 
diagnosed cancer in men in the Western countries, 
represents a public health problem with unmet 
therapy. Signaling through the androgen receptor 
(AR) plays an essential role in the initiation and 
progression of prostate cancer.   Androgen-depriva-
tion therapy (ADT) is used as a first-line treatment 
for metastatic prostate cancer, in which AR continues 
to be expressed and active.  After significant clinical 
response, however, patients with advanced prostate 
cancer consistently relapse with a more aggressive 
form of PCa known as castration-resistant PCa 
(CRPC).   
 Several mechanisms have been suggested to 
mediate AR reactivation during CRPC progression, 
including AR gene amplification or overexpression, 
expression of splice variants, AR mutations – all of 
these conferring ligand promiscuity and/or ligand-
independent activity that lead to cancer cell pro-
liferation.  Since the available anti-androgens have 
low affinity for AR and cannot completely block 
androgen action, especially in the presence of 
increased AR levels and AR variants, the discovery 
of novel potent and antagonistic blockers of AR  is 
very important.  
 Kai and Levenson (2011) have previously 
demonstrated that Res inhibits the activity and 
decreases levels of AR in the androgen-dependent 
cell line LNCaP.  The AR in these cells bear a 
mutation T877A in the ligand binding domain that 
affects the response to androgens and anti-androgens 
(Mahmoud et al., 2013; Otsuka et al., 2011). 
Although initially isolated from lymph node 
metastasis, LNCaP cells in tissue culture represent a 
relatively “non-aggressive” stage of PCa as these 
cells form tumors with much difficulty and do not 
form metastasis in xenografts.   
 In contrast, 22Rv1 cells are castrate-resistant 
cells derived from a xenograft that was serially 
propagated in mice after castration-induced 
regression and relapse of the parental, androgen-
dependent CWR22 xenograft (Sramkoski et al., 
1999).  In pathophysiology, this represents a late, 
aggressive stage of PCa expressing 114/110 kDa full-
length and truncated 80 kDa AR variants (Guo et al., 
2009).   
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 The goal of the current study was to examine 
the effects of Res and the natural analogs of Res (3M-
Res, Pic, and Pter) as potential new AR blockers in 
22Rv1 cells.  In this study, Res and Res analogs 
inhibited cell proliferation and full-length as well as 
truncated AR expression in 22Rv1 cells.  The 
inhibitory effect on truncated AR levels was most 
prominent at the higher concentrations of the tested 
compounds.   The study results provide substantial 
evidence for plant-derived stilbenes as promising 
compounds for use, probably in combination with 
other anti-androgens, as inhibitors of AR signaling 
and thereby diminishing progression and worsening 
of CRPC.  
 
MATERIALS AND METHODS 
  Chemicals.  Resveratrol (Res) and piceatannol 
(Pic) were purchased from Sigma-Aldrich (St. Louis, 
MO) and Calbiochem-Novabiochem (San Diego, 
CA), respectively.  Trimethoxy-resveratrol (3M-Res) 
and pterostilbene (Pter) were chemically synthesized 
at the USDA, ARS, National Products Utilization 
Research Unit in Oxford, MS, as previously 
described (Paul et al., 2010; Rimando et al., 2002). 
Structures of the synthesized compounds were 
confirmed by nuclear magnetic resonance 
spectroscopy and mass spectrometry.  All com-
pounds had ≥ 99% purity and were dissolved in high 
purity DMSO and stored in the dark at -200C. 
 Cell culture.  The 22Rv1 cells were grown in 
RPMI 1640 media (GIBCO, Grand Island, NY) 
containing 10% Fetal Bovine Serum (GIBCO, Grand 
Island, NY) and 1% antibiotic-antimycotic (GIBCO, 
Grand Island, NY) at 37oC and 5% CO2 as previously 
described for other prostate cancer cells (Dias et al., 
2013).  For experiments involving treatment with Res 
and analogs, media was replaced with phenol red-free 
RPMI-1640 (GIBCO, Grand Island, NY) containing 
5% charcoal-stripped serum (GIBCO, Grand Island, 
NY) at least 8-10 h prior to treatment to eliminate 
hormonal background.   
 Cell proliferation assay. Cell viability was 
measured by the 3-(4,5-dimethylthazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay.  Briefly, 
22Rv1 cells were seeded at 3x103 cells/well density in 
96-well plates using usual media.  The media was 
changed to phenol red-free with 5% charcoal-stripped 
serum 8-10 h prior to treatment.  Fresh media (100 
μL), containing serial concentrations of Res, 3M-Res, 
Pter, and Pic, was added each day for 72 h, after 
which 20 μL of 5 mg/mL MTT (Sigma-Aldrich, St. 
Louis, MO) was added to the treatment media in the 
cells. After a 4 h incubation at 370 C, the media 
containing MTT was removed and the formazan 
crystals were dissolved in 100 μLof solvent (4 mM 
HCl and 0.1% TritonX-100 in isopropanol). The 
absorbance of the formazan at 590 nm was measured 
using Synergy-4 plate reader (BioTek Instruments 
Inc., Winooski, VT).  IC50 values were calculated by 
the linear interpolation method, using MS Excel 
software (Microsoft, Redmond, WA).   
Western blot analysis.  Western blot analysis 
was done as described previously (Dias et al., 2013; 
Li et al., 2013).  Briefly, 22Rv1 cells at 50-60% 
confluency were treated with selected concentrations 
of Res and Res analogs for 24 h.  The cells were 
subsequently lysed in RIPA buffer (ThermoFisher, 
Waltham, MA) containing protease and phosphatase 
inhibitor cocktail (ThermoFisher, Waltham, MA). 
The protein concentration in the lysates was 
measured using the Bio-Rad protein assay reagent 
(Bio-Rad Laboratories, Hercules, CA). Equal 
amounts of protein (50 μg) were resolved in 10% 
SDS-PAGE gel and transferred to a PVDF membrane 
by Mini-Trans-Blot Electrophoresis Transfer System. 
The membranes were subsequently probed with AR 
(N20) antibody (Santa Cruz Biotechnology, Dallas, 
TX).  β-actin (Santa Cruz Biotechnology, Dallas, TX) 
was used as a loading control. Signals were 
visualized using the chemiluminescent substrate 
Super-signal West Dura (ThermoFisher, Waltham, 
MA).  Densitometry was done using Image J 
software.   
Statistical analysis.  The differences between 
the values of experimental and control treatments 
were analyzed for statistical significance by two-tail 
Student t test. The p values ≤0.05 were considered to 
be significant.  
RESULTS 
Prostate cancer inhibition.  An examination 
on the growth of 22Rv1 castrate resistant prostate  
cancer cells treated with Res and the three natural 
analogs of Res (3M-Res, Pter, and Pic) was 
performed.  The cells were treated with various 
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concentrations of the analogs (1-100 µM) in phenol 
red-free RPMI 1640 media supplemented with 5% 
charcoal-stripped FBS for 3 days.  After treatment, a 
cell proliferation assay was done to assess the growth 
inhibitory activity of Res and analogs on 22Rv1 cells.  
All the tested compounds inhibited the growth of 
22Rv1 cells in a dose dependent manner, but with 
different potencies (Fig. 2).   
Figure 2. The effect of resveratrol and analogs on inhibition 
                 of cell growth. 
Supplemental:  Resveratrol and analogs inhibited growth of 22Rv1 
castrate-resistant prostate cancer cells. Cells were grown in media 
containing selected doses of resveratrol (Res), trimethoxy-resveratrol 
(3M-Res), pterostilbene (Pter), and piceatannol (Pic).  MTT assay was 
done with formazan measurements at 72 h.  Viable cells were plotted 
as a fraction of untreated cells (Ctrl) (which was set to 1).  Data 
represent the mean ± SE of three independent experiments in which 
each treatment (data point) was done in triplicates.  Statistical 
significance was determined by two-tail Student t test.  The p value ≤ 
0.05 was considered significant.  The IC50 values were calculated using 
the linear interpolation method with MS Excel software.  
 
 The cell growth inhibitory effect of Res and 
analog was determined by the IC50 values [50% 
inhibitory effect cell proliferation], using the liner 
interpolation method in MS Excel software.  IC50 of 
Res 149.92 μM, whereas the other three analogs 
exhibited a stronger effect on cell proliferation as 
indicated by lower IC50 values of 19.42, 13.88, and 
9.45 µM for Pter, Pic, and 3M-Res, respectively.  The 
3M-Res was the most potent among the Res analogs 
in inhibiting the growth of 22Rv1 cells, supporting 
the fact that replacement of all three hydroxy (OH) 
substituents with methoxy (OCH3) groups results in a 
greater growth inhibitory activity (Dias et al., 2013, 
Gosslau et al., 2008). 
 Resveratrol and analog inhibition of AR. 
 Since the growth inhibition of the castrate-resistant 
prostate cancer cells (22Rv1) by resveratrol and 
analogs may be related to modulation of AR, the AR 
protein levels were assessed by Western blot analysis 
(Fig. 3).  The 22Rv1 cells are known to express full-
length 114/110 kDa and truncated (80 kDa) AR 
variants (Guo et al., 2009).  The 80 kDa AR variant, 
which is truncated at the C-terminal, contains N-
terminal domain (NTD) and a DNA-binding domain 
(DBD), but lacks the ligand-binding domain (LBD) 
(Fig. 4A) (Dehm et al., 2011).  
 
 
 Figure 3. Inhibition of AR expression in 22Rv1 castrate 
 resistant prostate cancer cells. 
 
Supplemental:  Western blots (left) indicate the effect of (A) Res, (B) Pter, 
and (C) Pic on AR protein levels at selected concentrations along with 10 
nM R1881 (synthetic androgen); and 100 μM FL (flutamide - anti-
androgen) for 24 h.  -actin was used as a loading agent.  Graphical 
representation (right) is from quantitative analysis by Image J software.   
Control (Ctrl) was set as 1 and AR (     AR 114/110,      AR 80) levels are 
expressed relative to the control.  Data represent the mean ± SE of three 
independent trials.   *Significant at p < 0.05.                                   
 
 
 
 The 114/110 kDa AR variant was recognized as 
a single band at 110 kDa (AR114/110) while the 80 
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kDa AR variant (AR80) was recognized separately.  
The AR114/110, which has ligand-binding domain, 
responded to the ligand, synthetic androgen (R1881), 
and the nonsteroidal anti-androgen flutamide (FL), as 
indicated by the increase and decrease in AR levels 
upon treatment with R1881 and FL, respectively. 
AR80, however, did not respond to R1881, but 
responded to FL, suggesting different mechanisms of 
FL action than binding to the ligand-binding domain 
of AR.  
 Resveratrol treatment decreased AR114/110 
levels in these cells, but at a high concentration of 
100 µM, whereas AR80 levels were decreased in a 
dose dependent manner. Pterostilbene treatment 
initiated reduction of both AR114/110 and AR80 
levels, but only at the 100 µM concentration.  In 
contrast, treatment with Pic showed dose dependent 
lowering of both AR114/110 and AR80 levels with 
the effect being more prominent in the AR80 levels.  
 The 3M-Res did not produce a reliable dose-
dependent inhibition of either AR114/110 or AR80 
(data not shown).  The differential effects of Res and 
analogs on AR114/110 and AR80 may be due to 
difference in the interaction of these compounds with 
specific domains of the AR variants (Fig. 4). 
Cumulative analysis of changes in AR levels by 
R1881, FL and stilbenes at 50 and 100 μM 
concentrations is shown in Fig. 4B. 
 
DISCUSSION 
A mainstay therapy of prostate cancer depends 
on androgen deprivation to which most patients do 
respond, but relapse with a castrate-resistant clinical 
outcome. The AR remains constitutively active in 
several cases of CRPC, however, several cellular and 
molecular alterations are related to this post-castration 
activation of the AR, including in-complete blockade of 
AR-ligand signaling,  AR ampli-fications, AR 
mutations, aberrant AR co-regulator activities and AR 
splice-variant expression (Karantanos et al., 2013).  
Accumulating data suggests that both AR-dependent 
and AR-independent mechanisms are active and 
contribute to castrate-resistance (Kobayashi et al., 
2013). 
 
 
Figure 4. Regulation of full- length and truncated AR levels  
      in 22Rv1 cells by resveratrol and analogs. 
Supplemental:  A. Domain structure of full-length AR (110 kDa) and 
truncated AR (80 kDa) protein in 22Rv1 cells.  B. Graphical representa-tion 
of western blots quantitated by Image J software.   Res, 3M-Res, Pter, and 
Pic reduced the full-length AR (AR114/110) and truncated AR (AR80) levels 
at 50 M (left) and 100 M (right) concentrations.  R1881 is a synthetic 
androgen agonist, and Fl (flutamide is an anti-androgen.  Data 
represent the mean ± SE of three independent replicate trials, *P<0.05.   
  
 In the present study, the effect of Res and 
natural Res analogs on full-length and truncated AR 
in 22Rv1 cells were investigated.  The 22Rv1 cells 
are unique in harboring splice variants of AR lacking 
the ligand-binding domain (Tepper et al., 2002) that 
is frequently expressed (Libertini et al., 2007).  This 
AR is up-regulated in prostate cancer progression and 
promotes androgen-independent growth resistance 
(Guo et al., 2009).  In earlier studies, Res was shown 
to induce down-regulation of AR in LNCaP cells 
(harboring a point mutation in AR protein) by 
inducing protein degradation through the caspase-3 
proteolytic pathway (Kai and Levenson, 2011).  From 
our earlier observations that Res can inhibit AR 
expression in LNCaP cells led to consideration 
whether Res and Res natural analogs would have a 
similar effect on the AR expression in castrate-
resistant 22Rv1 cells.  
Our data revealed that 3M-Res was  
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approximately 16-fold the efficiency of Res in 
inhibiting proliferation of 22Rv1 cells as indicated by 
their IC50 values (Fig. 2). It has been reported that the 
truncated isoform of AR (AR80) mediates the ligand-
independent AR activity responsible for cell 
proliferation (Marcias et al., 2010). Interestingly, all 
three analogs were almost equally effective in 
inducing growth-inhibitory activity at the higher 
concentrations, and were much more potent than Res. 
The current data support our earlier observation that 
replacement of all three hydroxy (OH) substituents of 
Res with methoxy (OCH3) groups results in greater 
growth inhibitory activity (Dias et al., 2013). 
 Thinking that the growth inhibition by Res and 
analogs in these cells may be related to modulation of 
AR, and to understand the effect of Res and Res 
analogs on the dynamics of the AR protein in 22Rv1 
cells, the cells were treated with the test compounds 
in increasing doses from 5-100 µM and subjected to a  
western blot analysis to determine the AR protein 
levels.  For controls, the cells were also treated with 
the synthetic androgen agonist R1881 and the anti-
androgen, FL.  R1881 enhanced and FL reduced the 
expression of AR114/110, while AR80 responded 
only to FL.  This action could be expected due to the 
lack of LBD in AR80. Only Pic demonstrated a dose-
dependent down-regulation in AR levels, whereas 
Res and Pter were effective only at the higher 
concentrations. Interestingly, 3M-Res did not produce 
any down-regulation of AR (data not shown) 
although the 3M-Res was more efficient than the 
other stilbenes in inhibiting the proliferation of 
22Rv1 cells.  
 An AR-independent inhibition mechanism 
mediated by 3M-Res may be active in these cells. Of 
note, the truncated isoform of AR (AR80) was down-
regulated more efficiently, as compared to the full-
length counterpart, by FL or the stilbenes, suggesting 
involvement of mechanisms other than AR binding. 
These observations were corroborated by a test 
comparison of the relative expression of the full-
length vis-à-vis the truncated AR with all the 
stilbenes at 50 and 100 µM concentrations.  
 Since the truncated AR can be down-regulated 
more effectively by the stilbenes than the full-length 
AR, this may possibly provide a target for therapeutic 
intervention using combinations of Res and Res ana-
logs in patients that relapse after androgen ablation 
and present a castration-resistant phenotype. 
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